文献速递病毒性肝炎

慢性丙型肝炎合并中重度肝病者死亡率增加:一项队列研究

Increased Mortality Among Persons With Chronic Hepatitis C With Moderate or Severe Liver Disease: A Cohort Study.
PubMed 文献 · Clin Infect Dis · 2017-01-01

该队列研究对964名有注射吸毒史的慢性HCV感染者进行瞬态弹性成像半年一次随访。结果显示,中度纤维化者全因和非意外死亡率升高,且无法准确预测从轻度向中度纤维化的转变。提示不应按纤维化分期延迟治疗。

要点

  • 中度纤维化者非意外死亡风险升高(aHR 1.66,95%CI 1.06-2.59)。
  • 现有因素无法准确预测轻度向中度纤维化转变(最佳模型C统计量0.72)。

核心结论

  • 延迟治疗任何慢性HCV感染者可能有害,因中度肝病者死亡风险已增加且疾病分期转变难以预测。

研究设计与样本

  • 在Baltimore对964名有注射吸毒史的慢性HCV感染者进行队列研究,2006至2014年每半年用瞬态弹性成像评估肝硬度。

主要发现

  • 基线时62%无/轻度纤维化,23%中度纤维化,15%重度纤维化/肝硬化。
  • 中度纤维化者非意外死亡率aHR 1.66(95%CI 1.06-2.59)。
  • 无人口学、行为或临床因素组合,以及硬度测量变化本身,能足够准确预测从轻度到中度纤维化的转变(最佳模型C统计量0.72)。

关键数值与推荐

  • 瞬态弹性成像中度纤维化界值8.0-12.3 kPa,重度纤维化/肝硬化界值>12.3 kPa。

临床怎么用

  • 对慢性HCV感染者不应因纤维化分期处于轻度或中度而延迟治疗,因中度疾病已有死亡风险增加且转变难以预测。

局限性

  • 研究人群为有注射吸毒史的城市居民,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the availability of curative treatment for hepatitis C virus (HCV) infection, because of cost, treatment is often denied until liver fibrosis has progressed to at least moderate fibrosis and, in some cases, cirrhosis. That practice is justified on assumptions that there are no medical consequences to having moderate disease and that disease stage transitions can be anticipated. METHODS: We performed transient elastography on 964 people chronically infected with HCV with a history of injection drug use living in Baltimore, Maryland. Liver stiffness was evaluated semiannually from 2006 to 2014 using validated cutoffs for moderate fibrosis (8.0-12.3 kPa) and severe fibrosis/cirrhosis (>12.3 kPa). RESULTS: Among 964 persons, 62%, 23% and 15% had baseline measurements suggestive of no/mild fibrosis, moderate fibrosis, and severe fibrosis/cirrhosis, respectively. All-cause and nonaccidental mortality were elevated in persons with moderate fibrosis (adjusted hazard ratio [aHR], 1.42 [95% confidence interval {CI}, .96-2.11]; aHR, 1.66 [95% CI, 1.06-2.59], respectively) after adjustment for sociodemographics, substance use, and human immunodeficiency virus status. Despite the increased risk of mortality among those with moderate fibrosis, no combination of demographic, behavioral, and clinical factors, nor changes in stiffness measurements themselves could predict the transition from mild to moderate fibrosis with sufficiently high diagnostic accuracy (C-statistic = 0.72 for best-performing model). CONCLUSIONS: Delaying treatment for anyone chronically infected with HCV regardless of fibrosis stage may be detrimental given the increased risk of mortality even for those with moderate disease and the inability to predict the transition from mild to moderate disease.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cepeda JA, Thomas DL, Astemborski J, et al. Increased Mortality Among Persons With Chronic Hepatitis C With Moderate or Severe Liver Disease: A Cohort Study. Clin Infect Dis. 2017. PMID: 28329108. doi:10.1093/cid/cix207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。